Basilar Artery Occlusion Clinical Trial
Official title:
Intravenous Tenecteplase Plus Endovascular Thrombectomy Versus Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion -a Multicenter, Randomized Controlled, Clinical Trial
To assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
Status | Recruiting |
Enrollment | 332 |
Est. completion date | March 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery; 2. Time from stroke onset to randomization within 4.5-24 hours of estimated time of basilar artery occlusion; 3. Patient's age=18 years; 4. Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In cases of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery; 5. Patients presenting with acute ischemic stroke eligible using standard criteria (except for time window) to receive both endovascular thrombectomy and intravenous thrombolysis; 6. Baseline National Institutes of Health Stroke Scale (NIHSS) score= 10 at the time of neuroimaging; 7. The patient or patient's legal representative signs the informed consent form. Exclusion Criteria: 1. CT or MR evidence of intracerebral hemorrhage (the presence of < 10 microbleeds is allowed); 2. Pre-stroke modified Rankin scale (mRS) score of = 2; 3. Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) <5; 4. Pregnant or lactating women; 5. Allergy to contrast agent or nitinol alloy; 6. Life expectancy<1 year; 7. CTA/MRA/DSA show vascular tortuosity, vascular variation or artery dissection, which would make it difficult to perform endovascular treatment; 8. Participating in other clinical trials; 9. Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg, which cannot be controlled by antihypertensive drugs; 10. Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; or oral anticoagulant with international normalized ratio (INR) > 1.7, or novel oral anticoagulant within prior 48 hours; 11. Blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L), platelet< 100*109/L; 12. Renal insufficiency defined as serum creatinine >2.0 mg/dl (or 176.8 ยต mol/l) or a glomerular filtration rate <30 mL/min or the need for hemodialysis or peritoneal dialysis; 13. Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc); 14. The patient has acute ischemic cerebral infarction within 3 months from randomization; 15. The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis; 16. The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition; 17. CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle; 18. Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination; 19. CTA/MRA/DSA show both anterior and posterior circulation large vessel occlusion; 20. Patients with intracranial tumors (except small meningiomas); 21. Patients who received intravenous thrombolytics treatment before the randomization; |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of University of Science and Technology of China | Hefei | Anhui |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of University of Science and Technology of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Overall mortality at 7 (± 2 days) and 90 (± 14 days) | evaluate death rate | 7 (± 2 days) and 90 (± 14 days) after procedure | |
Other | Symptomatic intracerebral hemorrhage (sICH) within 72 hours | SICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by =4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death | Within 72 hours after procedure | |
Other | Any intracerebral hemorrhage within 72 hours | Evaluate intracerebral hemorrhage | Within 72 hours after procedure | |
Primary | Proportion of patients with modified Rankin Score 0-2 at day 90 (±14 days) | modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90 (± 14 days) after procedure | |
Secondary | Proportion of patients with modified Rankin Score 0-3 at day 90 (±14 days) | modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90 (± 14 days) after procedure | |
Secondary | Ordinal Shift analysis of modified Rankin Score at day 90 (±14 days) | modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90 (± 14 days) after procedure | |
Secondary | Score on the NIHSS at 24 hours | The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit. | 24 hours after procedure | |
Secondary | Score on the NIHSS at 5-7 days or discharge | The NIHSS is an ordinal hierarchical scale to evaluate the severity of stroke by assessing a patient's performance. Scores range from 0 to 42, with higher scores indicating a more severe deficit. | 5-7 days or discharge after procedure | |
Secondary | Proportion of patients with modified Rankin Score 0-1 at day 90 (±14 days) | modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90 (± 14 days) after procedure | |
Secondary | Proportion of patients with modified Rankin Score 0-4 at day 90 (±14 days) | modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death) | 90 (± 14 days) after procedure | |
Secondary | Score on the EuroQoL 5-dimensions 5-level (EQ5D-5L) at 90 days (±14 days) | Health-related quality of life, assessed with EQ-5D-5L | 90 (± 14 days) after procedure | |
Secondary | level of activities of daily living (Barthel index, BI) at 90 days (±14 days) | Level of activities of daily living | 90 (± 14 days) after procedure | |
Secondary | Successful reperfusion (Extended thrombolysis in cerebral infarction [eTICI] score 2b50-3) on digital substraction angiography (DSA) prior to thrombectomy | Evaluate effect of intravenous thrombolysis on reperfusion | within 5 minutes at angiography | |
Secondary | Successful reperfusion on final angiography of thrombectomy | Evaluate effect of thrombectomy on reperfusion | Within 5 minutes at final angiography of thrombectomy | |
Secondary | Successful recanalization on CT or MR angiography within 72 hours | Evaluate vascular patency after treatment | Within 72 hours after procedure | |
Secondary | Infarct volume (Posterior Circulation Acute Stroke Prognosis Early Computed Tomography Score, PC-ASPECTS) evaluated on CT or MRI within 72 hours | PC-ASPECTS=10 indicates a normal scan, PC-ASPECTS=0 indicates early ischemic changes or hypoattenuation in all above territories. 1 or 2 points each are subtracted for early ischemic changes or hypoattenuation in: left or right thalamus, cerebellum or posterior cerebral artery territory, respectively (1 point); any part of midbrain or pons (2 points) | Within 72 hours after procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01717755 -
Basilar Artery International Cooperation Study
|
N/A | |
Recruiting |
NCT06101667 -
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
|
N/A | |
Recruiting |
NCT05615038 -
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
|
N/A | |
Recruiting |
NCT05105633 -
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
|
Phase 2/Phase 3 | |
Recruiting |
NCT05320263 -
Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol
|
N/A | |
Not yet recruiting |
NCT04177615 -
Randomized Assessment of Rapid Endovascular Treatment in Basilar Artery Occlusion Stroke in 115 Hospital
|
N/A | |
Recruiting |
NCT05827042 -
Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion
|
Phase 3 | |
Active, not recruiting |
NCT02737189 -
Basilar Artery Occlusion Chinese Endovascular Trial
|
N/A | |
Not yet recruiting |
NCT05580822 -
Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion
|
Phase 2 | |
Completed |
NCT04751708 -
Endovascular Treatment for Acute Basilar Artery Occlusion
|
N/A | |
Recruiting |
NCT05512910 -
Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)
|
Phase 4 | |
Recruiting |
NCT05402878 -
OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION
|
||
Recruiting |
NCT05631847 -
Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke
|
N/A |